SS Innovations International Inc. (NASDAQ: SSII), a developer of innovative surgical robotic technologies, reported record second-quarter revenue of $13.9 million, a 39.4% increase from $10.0 million in the same period last year. The company also announced that first-half revenue reached $25.0 million, a 65.6% jump from $15.1 million in the first half of 2025. This growth underscores the continued momentum for its SSi Mantra surgical robotic platform, which is expanding its global footprint.
The company's SSi Mantra installations rose 30.4% to 30 systems during the quarter, bringing the total installed base to 224 systems across 12 countries. Cumulative surgeries performed using the platform reached 12,272, reflecting growing clinical adoption. System installations remain the primary commercial growth driver, while the company's telesurgery achievements are extending the clinical profile of SSi Mantra, showcasing its capabilities beyond traditional surgical settings.
Gross profit for the second quarter increased 20.0% to $7.1 million, though gross margin declined to 50.9% from 59.1% in the year-earlier quarter. For the first half, gross profit rose 77.5% to $12.4 million, with an improved gross margin compared to the prior year. These financial results highlight the company's ability to scale revenue while managing costs, despite margin pressures in the quarter.
The significance of this announcement extends beyond the financial figures. SS Innovations is positioning itself for major regulatory milestones that could serve as important catalysts. The company is targeting FDA clearance for SSi Mantra by the first quarter of 2027 and EU CE marking by the end of 2026. Achieving these approvals would open doors to the U.S. and European markets, potentially transforming the competitive landscape in surgical robotics. Currently, the market is dominated by a few key players, and a new entrant with a proven track record could offer hospitals and surgeons more options, potentially reducing costs and improving access to robotic surgery.
For the industry, the rapid growth in installations and surgeries indicates a rising demand for robotic-assisted procedures, particularly in regions where such technology was previously limited. The expansion across 12 countries suggests that the platform is adaptable to diverse healthcare environments, from advanced medical centers to emerging markets. This could have a profound impact on patient care, as robotic surgery often results in less pain, shorter hospital stays, and faster recovery times compared to traditional open surgery.
For investors, the strong revenue growth and strategic regulatory timeline provide a clear picture of the company's trajectory. However, the decline in gross margin in the second quarter warrants attention, as it may reflect increased costs associated with scaling production or expanding into new markets. The company's ability to manage these costs while pursuing regulatory approvals will be crucial for long-term profitability.
As SS Innovations continues to expand its installed base and advance toward regulatory clearances, its progress will be closely watched by healthcare providers, investors, and competitors alike. The company's success could not only reshape the surgical robotics market but also improve surgical outcomes for patients worldwide.
